Increases in Autoantibody Level Associated with Degenerative Changes in the Intestinal Mucosa in Liver Cirrhosis.
intestinal autoantibodies
liver cirrhosis
liver regeneration
portal hypertension
portal hypertensive colonopathy
Journal
Clinical and experimental gastroenterology
ISSN: 1178-7023
Titre abrégé: Clin Exp Gastroenterol
Pays: New Zealand
ID NLM: 101532800
Informations de publication
Date de publication:
2020
2020
Historique:
received:
28
05
2020
accepted:
12
08
2020
entrez:
9
9
2020
pubmed:
10
9
2020
medline:
10
9
2020
Statut:
epublish
Résumé
Portal hypertensive colonopathy is a consequence of portal hypertension that develops in hepatic cirrhosis. Pathological processes occurring in intestinal epithelium cells can be revealed by changes in the autoantibody titers to intestinal antigens. It is important both in diagnosis and in the evaluation of the treatment effectiveness. To investigate the effect of portal hypertension in patients with liver cirrhosis on degenerative processes in the walls of the small and large intestines after stimulation of liver regeneration with cryoprecipitate. Thirty-six patients with liver cirrhosis underwent a procedure for percutaneous introduction of cryoprecipitate into the liver tissue. Before and 1 year after it, all the patients were measured for portal blood flow parameters, performed colonoscopy with biopsy, and determined autoantibodies to intestinal antigens (ItM, SCM) in the blood. Comparative analyses of changes in the large intestine mucosa before and after reducing portal hypertension by stimulating liver regeneration with cryoprecipitate were conducted. Here, we show that the degenerative process in the mucosa of the intestines increases, despite the positive dynamics of portal blood flow parameters after the liver regeneration. Autoantibodies values for the intestine antigens were higher than normal in 22 of the 36 patients after 1 year of introduction of cryoprecipitate into the liver. Morphological analysis of the intestinal wall showed the presence of edema/mucosal atrophy and neutrophilic/lymphocytic-histiocytic infiltration in 28 of the 36 patients. Changes in autoantibodies to intestinal antigens are an informative method for diagnosing colonopathy and enteropathy at early stages, providing the possibility to administer proper timely treatment. Patients with hepatic cirrhosis are recommended to have their intestinal microflora tested and be administered drugs that improve their composition.
Sections du résumé
BACKGROUND
BACKGROUND
Portal hypertensive colonopathy is a consequence of portal hypertension that develops in hepatic cirrhosis. Pathological processes occurring in intestinal epithelium cells can be revealed by changes in the autoantibody titers to intestinal antigens. It is important both in diagnosis and in the evaluation of the treatment effectiveness.
PURPOSE
OBJECTIVE
To investigate the effect of portal hypertension in patients with liver cirrhosis on degenerative processes in the walls of the small and large intestines after stimulation of liver regeneration with cryoprecipitate.
METHODS
METHODS
Thirty-six patients with liver cirrhosis underwent a procedure for percutaneous introduction of cryoprecipitate into the liver tissue. Before and 1 year after it, all the patients were measured for portal blood flow parameters, performed colonoscopy with biopsy, and determined autoantibodies to intestinal antigens (ItM, SCM) in the blood. Comparative analyses of changes in the large intestine mucosa before and after reducing portal hypertension by stimulating liver regeneration with cryoprecipitate were conducted.
RESULTS
RESULTS
Here, we show that the degenerative process in the mucosa of the intestines increases, despite the positive dynamics of portal blood flow parameters after the liver regeneration. Autoantibodies values for the intestine antigens were higher than normal in 22 of the 36 patients after 1 year of introduction of cryoprecipitate into the liver. Morphological analysis of the intestinal wall showed the presence of edema/mucosal atrophy and neutrophilic/lymphocytic-histiocytic infiltration in 28 of the 36 patients.
CONCLUSION
CONCLUSIONS
Changes in autoantibodies to intestinal antigens are an informative method for diagnosing colonopathy and enteropathy at early stages, providing the possibility to administer proper timely treatment. Patients with hepatic cirrhosis are recommended to have their intestinal microflora tested and be administered drugs that improve their composition.
Identifiants
pubmed: 32904688
doi: 10.2147/CEG.S263176
pii: 263176
pmc: PMC7457723
doi:
Types de publication
Journal Article
Langues
eng
Pagination
315-320Informations de copyright
© 2020 Karpova et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Case Rep Gastrointest Med. 2018 Oct 18;2018:9430701
pubmed: 30498606
Gastrointest Endosc. 2005 Oct;62(4):529-34
pubmed: 16185966
Rev Esp Enferm Dig. 2017 Dec;109(12):856-862
pubmed: 28747052
J Gastroenterol. 2013 May;48(5):633-9
pubmed: 22968470
J Hepatol. 2012 Jun;56(6):1221-3
pubmed: 22406521
Nat Rev Gastroenterol Hepatol. 2018 Jul;15(7):397-411
pubmed: 29748586
World J Gastroenterol. 2014 Nov 14;20(42):15624-31
pubmed: 25400446
World J Gastroenterol. 2013 Nov 28;19(44):7992-9
pubmed: 24307792
World J Gastroenterol. 2019 Oct 21;25(39):5897-5917
pubmed: 31660028
J Hepatol. 2017 Nov;67(5):1084-1103
pubmed: 28526488
Gastrointest Endosc. 2015 Sep;82(3):469-76.e2
pubmed: 25841578
Hepatology. 2018 Apr;67(4):1485-1498
pubmed: 29113028
Clin Liver Dis. 2014 May;18(2):389-406
pubmed: 24679502
World J Hepatol. 2015 Feb 27;7(2):127-38
pubmed: 25729469
Hepatol Int. 2018 Feb;12(Suppl 1):24-33
pubmed: 28550391